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Multiple defects in apoptotic pathways have been described in peripheral neuroblastic tumours (NTs). Mitosis–karyorrhexis index
(MKI) is a reliable morphological marker identifying favourable and unfavourable NTs. The extent to which apoptotic processes
contribute to determine the clinical significance of MKI is still undefined. Apoptosis was investigated in a series of 110 peripheral NTs
by comparing MKI to immunohistochemical and molecular apoptotic features. High MKI was found in 55 out of 110 NTs (50%) and
was associated with advanced stage (P¼0.007), neuroblastoma (NB) histological category (P¼0.024), MYCN amplification
(Po0.001), and poor outcome (P¼0.011). Overall survival probability was 45% in patients with high MKI compared to 73% in
patients with low MKI. In the same 110 NTs, the expression of Bcl-2, Bcl-XL, Bax and Mcl-1 was studied by immunohistochemistry,
but no significant associations were found with clinicohistological features. Microarray analysis of apoptotic genes was performed in 40
out of 110 representative tumours. No significant association was found between the expression of apoptotic genes and MKI or
clinicohistological features. Proliferative activity was assessed in 60 out of 110 representative tumours using Ki67 immunostaining, but
no significant correlations with MKI or clinicobiological features were found. In NTs, the combination of apoptosis and proliferation as
expressed by MKI is a significant prognostic parameter, although neither of them is per se indicative of the clinicobiological behaviour
and outcome.
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Peripheral neuroblastic tumours (NTs) are embryonal tumours of
the sympathetic nervous system that originate during fetal or early
postnatal life as result of developmental defects during the normal
differentiation from neural crest-derived progenitor cells to
mature sympathetic neuronal cells (Nakagawara and Ohira,
2004). Morphologically, peripheral NTs can range from undiffer-
entiated, truly malignant neuroblastoma (NB), via ganglioneuro-
blastoma (GNB) to well differentiated benign ganglioneuroma
(GN). Clinical behaviour of NBs and GNBs is very heterogeneous
since they can often regress spontaneously in patients less than 1
year of age, while they tend to behave aggressively in those over
this age (Evans et al, 1976; De Bernardi et al, 2003). Accordingly,
among patients with NB or GNB, different risk categories – defined
as high, intermediate and low risk – can be identified according to
clinicobiological features (Brodeur, 2003). Accumulating evidence
suggests that tumour regression is at least in part regulated by
developmentally programmed neuronal cell death and/or differ-
entiation that are similar to the phenomena occurring in normal
sympathetic neurons during their development (Nakagawara,
2001). Likewise, failure to activate apoptotic programmes in
response to the exposure to cytotoxic drugs may contribute to the
resistance of NT cells to anticancer treatment (Fulda and Debatin,
2003).
Apoptosis is a form of programmed cell death involved in
embryonic development and normal tissue omeostasis. The
process can be triggered through two major pathways: (i)
extracellular signals such as members of the tumour necrosis
factor family can activate the death receptor-mediated extrinsic
route; or alternatively (ii) stress signals such as DNA damage,
hypoxia and loss of survival signals can activate the mitochondria-
Received 7 February 2006; revised 3 May 2006; accepted 11 May 2006;
published online 6 June 2006
*Correspondence: Dr S Uccini; E-mail: stefania.uccini@uniroma1.it
British Journal of Cancer (2006) 95, 49–55
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sdependent intrinsic route (Evan and Littlewood, 1998). Both
pathways involve the activation of a series of enzymes called
caspases, a family of proteases that cleave after aspartic acid
residues, but while each pathway has an independent group of
‘initiating’ caspases, both converge to utilise the same group of
‘effector’ caspases that execute the final cell death programme
(Thornberry and Lazebnik, 1998). As a consequence, apoptotic
cells, characterised at the end-stage by DNA endonuclease cleavage
yielding 180 base pair fragments, acquire typical morphologic
aspects such as condensed and fragmented nuclear material,
usually accompanied by condensed eosinophilic cytoplasm (Majno
and Joris, 1995).
In NB, multiple defects in mediators of apoptosis have been
described and, among them, the increased expression of anti-
apoptotic molecules such as Bcl-2 (Castle et al, 1993) and the
decrease sensitivity to tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL)-induced apoptosis secondary to the
inactivation of caspase 8 (Hopkins-Donaldson et al, 2000; Teitz
et al, 2000) appear to be the most consistent findings in aggressive
tumours. The relative contribution of each of these numerous
defects to spontaneous tumour regression or progression, how-
ever, remains incompletely understood.
A further critical molecule in the modulation of apoptosis in
response to a series of stresses including DNA damage, hypoxia or
proliferative signals is p53, whose stabilization leads cells to
undergo either a cell cycle arrest or apoptosis (Prives and Hall,
1999). Cells harbouring an impaired p53 can survive and
proliferate inappropriately and this event can result in cancer
development (Prives and Hall, 1999). In NB, a tumour that usually
shows an initial response to chemotherapy but tends to relapse as
drug-resistant disease, the inactivation of p53 via mutational or
nonmutational mechanisms could eventually represent one of the
most critical factors of therapeutic failure (Tweddle et al, 2003).
Recently, gene expression profiling of human tumours has
become available and several hundreds of genes differentially
expressed in favourable and unfavourable NB subsets have been
identified (Alaminos et al, 2003; Ohira et al, 2003). As it is unlikely
that hundreds of specific and coordinated molecular alterations
are required to transform a neural crest-derived progenitor cell to
tumour cell, further studies could potentially identify the few
seminal genes – maybe including apoptotic genes – that play a key
role in the disruption of normal gene transcription resulting in the
peripheral NT phenotype.
In the present study, we investigated the significance of
apoptotic processes in a series of newly diagnosed peripheral
NTs. Our results confirm that high MKI is associated with
unfavourable clinical and biological features, but does not
correlate with any specific apoptotic gene profile. Neither
apoptosis nor proliferation is per se indicative of clinicobiological
behaviour and outcome.
MATERIALS AND METHODS
Patients
Primary tumour samples were obtained by surgery from 110
children with newly diagnosed NT presenting between January
1985 and June 2002 to the Department of Pediatrics at La Sapienza
University, the Division of Oncology at Bambino Gesu ` Children’s
Hospital and the Division of Oncology at Royal Liverpool
Children’s NHS Trust Alder Hey. No selection criteria were
applied except for the availability of adequate frozen tumour tissue
for immunohistochemical and molecular analyses.
Patients, 60 males and 50 females, were aged from 1 day to 192
months (median, 20.5). Primary site was adrenal in 57 patients,
abdominal nonadrenal in 30, thoracic in 21, and cervical in two.
The 110 patients were staged according to the International
Neuroblastoma Staging System (INSS) (Brodeur et al, 1993): 21
patients were at stage 1, 23 at stage 2, 17 at stage 3, 34 at stage 4,
and 15 at stage 4S.
As of June 2005, the median follow-up for the 110 patients was
88.5 months (range: 1 day to 234 months). In 66 patients either
disease-free (DF, n¼64) or alive with disease (AWD, n¼2) at that
time, a median follow-up of 124.5 months (range: 45–234 months)
was observed. In 44 patients either dead of disease (DOD, n¼42)
or dead of complications (DOC, n¼2), a median follow-up of 16
months (range: 1 day to 120 months) was recorded.
Tumours were classified according to the International Neuro-
blastoma Pathology Classification (INPC) (Shimada et al, 1999a) as
follows: 90 NBs and 20 GNBs. The MKI, defined as the number of
tumour cells in mitosis or karyorrhexis (morphologically recog-
nizable by ruffling, blebbing and condensation of nuclear
cromatin) out of 5000 tumour cells, was determined according to
the INPC and categorized as low (o2%, equivalent to o100/5000)
or high (X2%, equivalent to X100/5000).
Institutional written informed consent was obtained from the
patient’s parents or legal guardians. The study underwent ethical
review and approval according to local institutional guidelines.
Tumour sample handling
At diagnosis, part of the tumour sample was formalin-fixed and
paraffin-embedded for histological examination; a part was snap
frozen in liquid nitrogen and stored at  801C until Southern blot
for the determination of MYCN copy number was performed as
each patient was diagnosed (Dominici et al, 1989). Frozen tumour
samples were also used to prepare the cryostat sections for the
immunohistochemical analysis and to extract RNA for apoptotic
gene array analysis.
Immunohistochemistry
Frozen sections, 4mm, from the 110 tumours were acetone-fixed
and then incubated with a MoAb directed against Bcl-2 (Dako,
Glostrup, Denmark), and rabbit polyclonal antibodies against Bcl-XL,
Bax and Mcl-1 (generous gift from John C Reed, The Burnham
Institute, La Jolla, CA, USA). Indirect avidin-biotin immunoper-
oxidase staining was performed (Vectastain, Vector Laboratories,
Burligame, CA, USA). The reaction product was revealed by 0.2%
hydrogen peroxide and 0.6% 3,3-diaminobenzidine (Sigma, Saint
Louis, MI, USA). Slides were counterstained with Mayer’s
haematoxylin. Cases were categorized as positive when 425% of
tumour cells were immunostained. Negative controls were
incubated with isotype matched nonimmune immunoglobulins
and yielded no staining.
Paraffin sections, 5mm, from 60 out of 110 representative
tumours selected according to MKI value, 30 with high and 30 with
low MKI, were deparaffinized, rehydrated and incubated with anti-
human p53 (Dako) and parkin (Cell Signaling Technology, Beverly,
MA, USA), and with MoAb Ki67 (Novocastra Laboratories,
Newcastle upon Tyne, UK). The antibodies were used at 1:50/
1:100 final dilutions. The antigen retrieval technique was
employed for the detection of all proteins. After repeated washings
with PBS, sections were incubated with avidin-biotin complex kit
(ABC-peroxidase, Dako). The reaction product was revealed by
0.2% hydrogen peroxide and 0.6% 3,3-diaminobenzidine
(Sigma). Slides were counterstained with Mayer’s haematoxylin.
Negative controls were incubated with isotype matched non-
immune immunoglobulins and yielded no staining. As positive
controls for parkin protein, paraffin sections from substantia nigra
samples obtained from human autoptic brain specimens were
utilized. Ki67 labelling index was determined by counting the
number of Ki67-positive cells out of 5000 tumour cells and was
expressed as the percentage positivity of each tumour for Ki67
immunostaining.
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sMicroarray analysis
Frozen sections, 10mm, from 40 out of 110 tumours selected
according to MKI value, 20 with high and 20 with low MKI, were
collected in test tubes. Total RNA was prepared using the RNA
FAST KIT (Molecular System, San Diego, CA, USA) and its
integrity was assessed by denaturating agarose gel electrophoresis
and spectrophotometry. Microarray analysis was performed as
described in detail in http://www.superarray.com. Briefly, total
RNA (3mg) was used as the template for biotin-labelled cDNA
probe synthesis and hybridised to APOPTOSIS oligonucleotide
arrays (GEArray Q Series Human Apoptosis Gene Array, Super-
Array Bioscience Corporation, Frederick, MD, USA), designed to
profile the expression of 96 key genes involved in apoptosis. Each
gene was tested in quadruplicate and the reaction was revealed by
chemiluminescence; the image was converted into a raw data file
using an image analysis software. Each array was spotted with a
negative control of pUC18, blank and housekeeping genes (b-actin,
GAPDH, cyclophilin A and ribosomal protein L13a). The relative
amount of a particular transcript was estimated by directly
comparing its signal intensity to the signal derived from GAPDH.
To make the data comparable, each signal was normalised against
the signal of housekeeping genes.
Statistical analysis
Associations between MKI and clinical, histological and molecular
features as well as between Bcl-2 family protein expression and
clinical, histological and molecular features were analysed using
2 2 contingency tables analysis and two tails Fisher’s Exact test
or w
2 test. Comparisons of Ki67 labelling index between subgroups
of tumours with different MKI and MYCN status were carried out
using one-way analysis of variance followed by Bonferroni
multiple comparisons post hoc test. Univariate and multivariate
regression analysis according to the Cox proportional hazard
model (Cox, 1972) and Kaplan and Meier survival curves
calculation (Kaplan and Meier, 1958) were carried out using the
software package SPSS 7.0 for Windows (SPSS Inc, Chicago, IL,
USA).
RESULTS
In total, 110 NTs were histologically grouped in two subsets
according to MKI determined following the INPC criteria
(Shimada et al, 1999a): low MKI when mitotic and karyorrhectic
cells were o2%, and high MKI when these cells were X2%. Out of
110 NTs, 55 (50%) had a high MKI and 55 (50%) a low MKI. The
distribution of MKI according to age at diagnosis (p1 year vs 41
year, 42 vs 68), primary site (nonadrenal vs adrenal, 53 vs 57),
clinical stage (1, 2, 4S vs 3 and 4, 59 vs 51), INPC histological
category (GNB vs NB, 20 vs 90), MYCN status (single copy vs
amplified, 94 vs 16) and outcome (DF and AWD vs DOD and DOC,
66 vs 44) was studied (Table 1). High MKI was significantly
associated with advanced stage (P¼0.007), NB category
(P¼0.024), MYCN amplification (Po0.001), and poor outcome
(P¼0.011). When Cox simple regression analysis was applied,
age at diagnosis over 1 year (P¼0.03), adrenal primary site
(P¼0.003), advanced stage (Po0.001), NB category (P¼0.01),
high MKI (P¼0.03), and MYCN amplification (Po0.001) were all
significantly associated with a shorter overall survival (Table 2). In
particular, overall survival probability was 45% in patients with
high MKI compared to 73% in patients with low MKI (Figure 1).
However, when Cox multiple regression analysis was applied, only
advanced stage and MYCN amplification (Po0.001 for both
variables) were independently associated with a shorter overall
survival (Table 2).
We also investigated the expression of four members of the Bcl-2
family (Bcl-2, Bcl-XL, Bax and Mcl-1) by immunohistochemistry
(IHC) on frozen sections obtained from the same 110 NTs.
Immunostaining for Bax and Bcl-XL was detected in the cytoplasm
of undifferentiated or poorly differentiated neuroblasts, whereas
positivity for Bcl-2 and Mcl-1 was detected in undifferentiated or
Table 1 Distribution of MKI according to clinical, histological and
prognostic features in 110 NTs
Features No. of cases Low MKI (%) High MKI (%) P value
Age at diagnosis
p1 year 42 23 (55) 19 (45) NS
41 year 68 32 (47) 36 (53)
Primary site
Nonadrenal 53 32 (60) 21 (40) NS
Adrenal 57 23 (40) 34 (60)
Clinical stage
1, 2, 4S 59 37 (63) 22 (37) 0.007
3, 4 51 18 (35) 33 (65)
INPC category
GNB 20 15 (75) 5 (25) 0.024
NB 90 40 (44) 50 (56)
MYCN status
Single copy 94 54 (57) 40 (43) o0.001
Amplified 16 1 (6) 15 (94)
Outcome
DF, AWD 66 40 (61) 26 (39) 0.011
DOD, DOC 44 15 (34) 29 (66)
Abbreviations: AWD: alive with disease; DF: disease free; DOD: dead of disease;
DOC: dead of complication; NS: nonsignificant.
Table 2 Simple and multiple Cox regression analysis of the correlations
between overall survival and clinical, histological and prognostic features in
110 NTs
Cox simple
regression
analysis
Cox multiple
regression
analysis
Features OS% RR (CI) P RR (CI) P
Age at diagnosis
p1 year 76 2.33 (1.15–4.72) 0.02 1.70 (0.77–3.77) NS
41 year 48
Primary site
Nonadrenal 75 2.65 (1.39–5.08) 0.003 1.63 (0.83–3.11) NS
Adrenal 45
Clinical stage
1, 2, 4S 92 14.46 (5.65–36.97) o0.001 7.01 (2.46–19.94) o0.001
3, 4 21
INPC category
GNB 86 6.28 (1.52–25.97) 0.01 3.01 (0.70–12.82) NS
NB 53
MKI
Low 73 2.61 (1.39–4.88) 0.03 1.19 (0.59–2.42) NS
High 45
MYCN status
Single copy 69 12.94 (6.18–27.12) o0.001 5.64 (2.42–13.13) o0.001
Amplified 0
Abbreviations: CI: 95% confidence interval; P: statistical probability; NS: statistically
not significant; OS%: percentage of overall survival; RR: relative risk.
Apoptotic features in NTs
S Uccini et al
51
British Journal of Cancer (2006) 95(1), 49–55 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
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Possible correlations between the expression of these proteins and
clinical, histological and prognostic features were also investigated,
but no significant associations were found except for Bcl-XL to be
expressed less frequently in cases over 1 year of age at diagnosis
(P¼0.021) (Table 3).
Nuclear localisation of p53 is essential for its normal function. In
NB, p53 although rarely mutated (Vogan et al, 1993), can still
be functionally inactivated through cytoplasmic sequestration
secondary to multiple mechanisms (Moll et al, 1995; Tweddle
et al, 2003) and, among them, even to a possible binding to parkin
protein (Nikolaev et al, 2003). In order to determine the relevance
of this phenomenon, we investigated the expression of p53 and
parkin in paraffin sections from 60 out of 110 NTs, 30 with low and
30 with high MKI. Parkin was consistently negative in all cases,
whereas p53 protein was observed in 47 out of 60 tumours (78%).
In all cases, immunostaining for p53 was detected at nuclear level
in approximately 25–50% of neuroblastic cells. Cytoplasmic
staining indicative of p53 sequestration was not detectable in this
series.
In order to extensively explore the expression of the genes
involved in apoptosis by using a technique more sensitive than
IHC, a microarray analysis designed to profile the expression of 87
key genes involved in apoptosis was performed in 40 out of 110
NTs, 20 with low and 20 with high MKI (Table 4). Four out of the
20 high MKI tumours were MYCN amplified. The results are
reported as median value for each transcript. The total number of
genes expressed in the low and high MKI subsets was comparable,
being 63 out of 87 and 66 out of 87, respectively, the mean number
of expressed genes. In total, 38 representative genes were selected
and grouped as belonging to the intrinsic route (n¼8), extrinsic
route (n¼16) or to caspases (n¼14). Among the genes involved
in the intrinsic route, those expressed at the highest level were Bax
and Bcl-2L2 (bcl-w gene) in both low and high MKI tumours,
immediately followed by survivin and Mcl-1. Among the genes
involved in the extrinsic route, TRAIL-R1 (DR4) and TRAIL-R2
(DR5) were expressed at the highest level in both low and high
MKI tumours, followed by TRAF-1, TRAF-6, Fas and Fas-ligand.
TRAIL was poorly expressed in both groups, even though the
amount of its mRNA was double in tumours with high MKI. In low
and high MKI tumours, p53 gene was equally expressed at very low
levels. Among the caspases, caspase 5, 7 and 14 were the genes
expressed at the highest level. In particular, caspase 7 and 14 were
the genes expressed at the highest level in low MKI tumours,
whereas caspase 7 and 5 those expressed at the highest level in high
MKI tumours. Only low levels of caspase 8 mRNA were
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Figure 1 Kaplan–Meier survival analysis according to low or high MKI in
110 patients with NT. Overall survival was 73% in those with low MKI
compared to 45% in those with high MKI (P¼0.03).
Table 3 Distribution of immunostaining for four members of Bcl-2 family according to clinical, histological and prognostic features in 110 NTs
Features Bcl-2 (%) P value Bcl-XL (%) P value Bax (%) P value Mcl-1 (%) P value
No. of +ve cases/No. of total cases 80/110 (73) NA 64/110 (58) NA 64/110 (58) NA 55/110 (50) NA
Age at diagnosis
p1 year (n¼42) 31 (74) NS 30 (71) 0.021 26 (62) NS 23 (55) NS
41 year (n¼68) 49 (72) 34 (50) 38 (56) 32 (47)
Primary site
Non adrenal (n¼53) 41 (77) NS 32 (60) NS 31 (59) NS 25 (47) NS
Adrenal (n¼57) 39 (68) 32 (56) 33 (58) 30 (53)
Clinical stage
1, 2, 4S (n¼59) 41 (70) NS 37 (63) NS 33 (56) NS 28 (48) NS
3, 4 (n¼51) 39 (77) 27 (53) 31 (61) 27 (53)
INPC category
GNB (n¼20) 14 (70) NS 10 (50) NS 11 (55) NS 13 (65) NS
NB (n¼90) 66 (73) 54 (60) 53 (59) 42 (47)
MKI
Low (n¼55) 41 (75) NS 32 (58) NS 29 (53) NS 28 (51) NS
High (n¼55) 39 (71) 32 (58) 35 (64) 27 (49)
MYCN status
Single copy (n¼94) 69 (73) NS 54 (57) NS 53 (56) NS 45 (48) NS
Amplified (n¼16) 11 (69) 10 (63) 11 (69) 10 (63)
Outcome
DF, AWD (n¼66) 51 (77) NS 42 (66) NS 38 (58) NS 36 (55) NS
DOD, DOC (n¼44) 29 (67) 22 (50) 26 (59) 19 (43)
Abbreviations: AWD: alive with disease; DF: disease free; DOD: dead of disease; DOC: dead of complication; NA: nonapplicable; NS: statistically not significant.
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selected genes were statistically analysed, but no obvious correla-
tion was shown with histological, clinical and prognostic features.
Owing to the difficulty in distinguishing mitotic cells from
other karyorrhectic tumour cells, in the Shimada system they are
counted together to give the MKI. Therefore, in order to evaluate
the relevance of the mitotic component in this series of NTs,
proliferative activity was investigated using Ki67 immunostaining
in paraffin sections from 60 NTs, 30 with low MKI (all MYCN
single copy) and 30 with high MKI (23 single copy and seven
MYCN amplified). Our results showed that the mean value of Ki67
labelling index (as defined in Materials and Methods) was
15.979.6 in the low MKI subset and 26.9716.3 in the high MKI
subset (P¼NS). However, when the Ki67 labelling index mean
value of the seven MYCN amplified NTs was calculated (48.975.5),
it was found to be significantly higher than in the 23 high MKI
(20.3712.0) and the 30 low MKI tumours (Po0.001) (Figure 2).
Among the 53 MYCN single copy tumours, no significant
difference in Ki67 labelling index was detected between those with
low or high MKI.
DISCUSSION
In the present study, we investigated the relevance of apoptosis in
peripheral NTs and the extent to which it contributes to determine
the clinical significance of MKI. Our results show that a high MKI
is associated with advanced stage, NB histological category, MYCN
amplification and poor outcome, thus confirming previous
findings reported by Shimada et al (1995, 1999b, 2001) and
Ambros et al (2002). However, when the levels of expression of key
genes involved in apoptosis were compared to either MKI and
clinicobiological features, no significant associations were found.
Multiple defects in intrinsic and extrinsic routes to apoptosis
and in caspases have been described in NTs. In the intrinsic route,
increased levels of the antiapoptotic protein Bcl-2 in primary NBs
correlate with unfavourable histology according to Shimada and
with MYCN amplification (Castle et al, 1993), and seem to promote
tumour cell survival (Ikeda et al, 1995). These findings, however,
were not confirmed by other reports in which no association with
MYCN amplification was found (Ikegaki et al, 1995). Similarly,
overexpression of Bcl-2 and Bcl-XL in NB cell lines was described
to block chemotherapy-induced apoptosis, thus suggesting that the
expression of these proteins may promote the drug resistance
characteristic of high-risk NBs (Dole et al, 1994, 1995). In the
present study, however, no significant associations between the
profile of genes involved in the intrinsic route to apoptosis and
histological, clinical and prognostic features of NTs were found. In
particular, microarray and immunohistochemical analysis demon-
strated that the expression of the antiapoptotic proteins Bcl-2, Bcl-XL
and Mcl-1 was not associated with either MYCN amplification or
other unfavourable prognostic features. However, taking into
account that survival and death signals converge on the
mitochondria through proapoptotic (Bax, Bak, Bid, Bad, Bik,
etc.) and antiapoptotic (Bcl-2, Bcl-XL, Mcl-1, A1 and Bcl-w)
proteins and that the former promote mitochondrial cytochrome c
efflux into cytosol while the latter inhibit the same efflux (Cory and
Adams, 2002), it is expected that the critical determinant of cell
survival is the overall balance between the pro- and antiapoptotic
members at mitochondrial level rather than the concentration of
the individual members.
Table 4 Apoptotic gene profile in 20 NTs with low MKI and 20 NTs
with high MKI: genes are grouped as belonging to the intrinsic route (n¼8),
extrinsic route (n¼16) or to caspases (n¼14)
Low MKI High MKI
Expressed genes/total no. of genes (range) 63/87 (26–87) 66/87 (34–86)
Genes Median Median
Intrinsic route
BAX 33352 30476
Bcl-2 5807 5043
BCL2A1 (bfl-1 gene) 1585 3159
BCL2L11 (bimL gene) 3043 2943
BCL2L2 (bcl-w) 26702 17443
Bcl-x 3367 4004
Mcl-1 14412 6726
Survivin 10675 15771
Extrinsic route
Fas 8287 8422
Fas ligand 6267 8218
FADD 1162 2387
TRAF1 11939 8068
TRAF2 1171 878
TRAF3 1560 1615
TRAF4 710 1196
TRAF5 1015 760
TRAF6 7602 8370
TRAIL 2181 4740
TRAIL-R1 (DR4) 15603 9182
TRAIL-R2 (DR5, KILLER) 37873 24555
TRAIL-R3 (DcR1) 4534 6042
TRAIL-R4 (DcR2) 1755 2392
TNFa 6183 3464
p53 1384 570
Caspases
CASP1 8026 8324
CASP2 3178 2559
CASP3 3133 5544
CASP4 2319 9125
CASP5 8891 18756
CASP6 3980 7378
CASP7 23764 14893
CASP8 5143 2663
CASP8AP 6881 3878
CASP9 445 1604
CASP10 4881 4154
CASP13 3572 3236
CASP14 20611 8726
CASPER 2264 3741
0
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Figure 2 Distribution of Ki67 labelling index (mean values795%
confidence interval) between subgroups of tumours with different MKI
(low vs high) and MYCN status (single copy vs amplified). Abbreviations –
MYCN : MYCN single copy; MYCNþ: MYCN amplified; CI: confidence
interval.
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most primary tumours and tumour cell lines, and this process can
be potentiated by cytotoxic agents (Ashkenazi and Dixit, 1999).
Two agonistic receptors for TRAIL, TRAIL-R1 (DR4) and TRAIL-
R2 (DR5, KILLER), and two antagonistic receptors, TRAIL-R3
(DcR1) and TRAIL-R4 (DcR2), have been identified (Ashkenazi
and Dixit, 1999). Activation of TRAIL-R1 and TRAIL-R2 activates
a signal transduction cascade involving several molecules and,
among them, caspase 8 and 10 (O ¨zo ¨ren and El-Deiry, 2003). In NB,
resistance to TRAIL-induced apoptosis has been preferentially
described in MYCN-amplified tumours and correlates with
inactivation of caspase 8 gene secondary to gene deletion or
silencing through DNA hypermethylation (Hopkins-Donaldson
et al, 2000; Teitz et al, 2000). Sensitivity to TRAIL-induced
apoptosis can be restored in caspase 8- and 10-deficient NB cell
lines by inducing a stable re-expression of caspase 8 (Muhlethaler-
Mottet et al, 2003). In the present study, among the genes involved
in the extrinsic route, TRAIL-R1 (DR4) and TRAIL-R2 (DR5) were
expressed at high level in both favourable and unfavourable NTs,
and no associations with MYCN amplification or other prognostic
features were shown. In agreement with previous studies reporting
a loss of caspase 8 expression in aggressive NBs (Hopkins-
Donaldson et al, 2000; Teitz et al, 2000; Stupack et al, 2006), in our
series a low expression of caspase 8 mRNA was found in all
tumours, with a tendency for high risk tumours to express even
lower levels.
TRAIL-R3 and TRAIL-R4, the two decoy receptors unable to
transduce the death signal, are thought to block TRAIL-induced
apoptosis by competing with TRAIL-R1 and TRAIL-R2 for the
ligand (Ashkenazi and Dixit, 1999; O ¨zo ¨ren and El-Deiry, 2003).
Hence, cells that express TRAIL-R3 and/or TRAIL-R4 at high levels
compared to TRAIL-R1 and/or TRAIL-R2 may use the decoys as
protection against TRAIL-induced apoptosis, although this is not
the only mechanism of resistance to TRAIL (Ashkenazi and Dixit,
1999; O ¨zo ¨ren and El-Deiry, 2003). Downregulation of TRAIL-R3
and TRAIL-R4 expression through hypermethylation of their
promoters has been previously described in NB cell lines (van
Noesel et al, 2002). The present findings, showing that TRAIL-R3
and TRAIL-R4 were expressed at substantially lower levels than
TRAIL-R1 and TRAIL-R2, are in agreement with this report and
seem to exclude that this mechanism of resistance to TRAIL is
active in NB tumours.
TRAIL-R2 has been identified as a transcriptional target of
p53 (Wu et al, 1997). In NB, p53 is rarely mutated (Vogan
et al, 1993) but can be functionally inactivated through
cytoplasmic sequestration (Moll et al, 1995). Several mechanisms
have been proposed (Tweddle et al, 2003) and, among them, a
possible binding to parkin protein (Nikolaev et al,
2003). Regardless of the mechanism – mutational or nonmuta-
tional – underlying p53 inactivation, this could eventually
represent one of the most critical factors of therapeutic failure in
NB tumours (Tweddle et al, 2003). Accordingly, in the
present study, the levels of p53 mRNA expression were very low
in both favourable and unfavourable tumours, with a tendency for
high-risk tumours to express even lower levels. Moreover, when
immunohistochemical analysis was carried out, immunostaining
for p53 was only detected in the nucleus of neuroblasts and parkin
protein was never detected. These findings suggest that p53
cytoplasmic sequestration is an infrequent event in NB tumours
and likely unrelated to the binding to parkin protein.
In the Shimada system, due to the difficulty in distinguishing
morphologically mitotic from karyorrhectic tumour cells, these
are counted together to give the MKI. In this study, the absence of
correlations between apoptotic features and MKI prompted us to
investigate whether and to what extent tumour cell proliferative
activity may also account for the different clinicobiological
behaviours. No significant differences in Ki67 labelling index
were demonstrated in the low vs high MKI subset of NTs, the only
difference being confined to the MYCN amplified tumours. A
previous report suggested that, since proliferating cells generally
outnumbers apoptotic cells, the resulting sum relies most heavily
on proliferation and this is the reason why a high MKI correlates
with a poor outcome in NTs (Gestblom et al, 1995). This
study confirmed that proliferating cells outnumber apoptotic cells
but also showed that proliferating cells are equally present in low
and high MKI tumours. A significantly higher proliferative activity
was only detected in the small subgroup of MYCN amplified
tumours.
In conclusion, the present findings confirm previous reports
indicating that MKI is in NTs a reliable morphological marker of
clinical behaviour and identifies favourable and unfavourable NTs
(Shimada et al, 1995, 1999b, 2001; Ambros et al, 2002). Our results
also show that karyorrhectic cells represent the end-stage of a
cascade of events leading to morphologically recognisable
apoptosis, although none of these individual events is able by
itself to determine the clinical relevance of the entire apoptotic
process. Neither proliferation nor apoptosis is per se indicative of
clinicobiological behaviour and outcome. In NTs, prognostication
still remains strongly dependent on the morphological assessment
of MKI.
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